Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Similar articles for PubMed (Select 21718390)

1.

Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.

Lampl C, You X, Limmroth V.

Eur J Neurol. 2012 Jan;19(1):142-8. doi: 10.1111/j.1468-1331.2011.03460.x. Epub 2011 Jul 1.

PMID:
21718390
2.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
4.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group.

Neurology. 2006 Mar 14;66(5):678-84. Epub 2006 Jan 25.

PMID:
16436649
5.

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

Clanet M, Kappos L, Hartung HP, Hohlfeld R; European IFNbeta-1a Dose-Comparison Study Investigators.

Mult Scler. 2004 Apr;10(2):139-44.

PMID:
15124757
6.

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.

Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A.

BMC Neurol. 2011 Oct 14;11:126. doi: 10.1186/1471-2377-11-126.

7.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
8.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.

Mult Scler. 2005 Aug;11(4):409-19.

PMID:
16042223
10.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229. Epub 2009 May 22.

PMID:
19465443
11.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.

Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.

12.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
13.

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.

Neurology. 2002 Nov 26;59(10):1507-17.

PMID:
12451189
14.

Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.

Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group.

Neurol Sci. 2007 Jun;28(3):127-32. Epub 2007 Jun 30.

PMID:
17603763
15.

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.

O'Connor P, Kinkel RP, Kremenchutzky M.

Mult Scler. 2009 Jun;15(6):728-34. doi: 10.1177/1352458509103173.

PMID:
19482863
16.

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S.

Clin Ther. 2004 Apr;26(4):511-21.

PMID:
15189748
17.

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators.

Neurology. 2005 Jul 12;65(1):40-7.

PMID:
16009883
18.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
19.

Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.

Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M.

Eur Neurol. 2013;70(1-2):35-41. doi: 10.1159/000346761. Epub 2013 May 14.

PMID:
23689307
20.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk